191 related articles for article (PubMed ID: 29743296)
1. YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT.
Kosnopfel C; Sinnberg T; Sauer B; Busch C; Niessner H; Schmitt A; Forchhammer S; Grimmel C; Mertens PR; Hailfinger S; Dunn SE; Garbe C; Schittek B
Mol Cancer Res; 2018 Jul; 16(7):1149-1160. PubMed ID: 29743296
[TBL] [Abstract][Full Text] [Related]
2. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
3. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Liao LZ; Chen CT; Li NC; Lin LC; Huang BS; Chang YH; Chow LP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379356
[TBL] [Abstract][Full Text] [Related]
4. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype.
Sinnberg T; Levesque MP; Krochmann J; Cheng PF; Ikenberg K; Meraz-Torres F; Niessner H; Garbe C; Busch C
Mol Cancer; 2018 Feb; 17(1):59. PubMed ID: 29454361
[TBL] [Abstract][Full Text] [Related]
5. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma.
Cheng PF; Shakhova O; Widmer DS; Eichhoff OM; Zingg D; Frommel SC; Belloni B; Raaijmakers MI; Goldinger SM; Santoro R; Hemmi S; Sommer L; Dummer R; Levesque MP
Genome Biol; 2015 Feb; 16(1):42. PubMed ID: 25885555
[TBL] [Abstract][Full Text] [Related]
6. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.
Sinnberg T; Sauer B; Holm P; Spangler B; Kuphal S; Bosserhoff A; Schittek B
Exp Dermatol; 2012 Apr; 21(4):265-70. PubMed ID: 22417301
[TBL] [Abstract][Full Text] [Related]
7. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
8. YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.
Lim JP; Shyamasundar S; Gunaratne J; Scully OJ; Matsumoto K; Bay BH
BMC Cancer; 2017 Mar; 17(1):201. PubMed ID: 28302118
[TBL] [Abstract][Full Text] [Related]
9. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin.
Khan MI; Adhami VM; Lall RK; Sechi M; Joshi DC; Haidar OM; Syed DN; Siddiqui IA; Chiu SY; Mukhtar H
Oncotarget; 2014 May; 5(9):2462-74. PubMed ID: 24770864
[TBL] [Abstract][Full Text] [Related]
10. Shrimp miR-S8 Suppresses the Stemness of Human Melanoma Stem-like Cells by Targeting the Transcription Factor YB-1.
Yang F; Wei J; Zhang S; Zhang X
Cancer Res; 2017 Oct; 77(20):5543-5553. PubMed ID: 28855207
[TBL] [Abstract][Full Text] [Related]
11. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation.
Wu K; Chen K; Wang C; Jiao X; Wang L; Zhou J; Wang J; Li Z; Addya S; Sorensen PH; Lisanti MP; Quong A; Ertel A; Pestell RG
Cancer Res; 2014 Feb; 74(3):829-39. PubMed ID: 24335958
[TBL] [Abstract][Full Text] [Related]
12. Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro.
Guo TT; Yu YN; Yip GW; Matsumoto K; Bay BH
Anat Rec (Hoboken); 2013 Jun; 296(6):891-8. PubMed ID: 23613305
[TBL] [Abstract][Full Text] [Related]
13. EMT-associated factors promote invasive properties of uveal melanoma cells.
Asnaghi L; Gezgin G; Tripathy A; Handa JT; Merbs SL; van der Velden PA; Jager MJ; Harbour JW; Eberhart CG
Mol Vis; 2015; 21():919-29. PubMed ID: 26321866
[TBL] [Abstract][Full Text] [Related]
14. Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells.
Castellana B; Aasen T; Moreno-Bueno G; Dunn SE; Ramón y Cajal S
Oncotarget; 2015 Nov; 6(35):38239-56. PubMed ID: 26512918
[TBL] [Abstract][Full Text] [Related]
15. Identifying and targeting determinants of melanoma cellular invasion.
Jayachandran A; Prithviraj P; Lo PH; Walkiewicz M; Anaka M; Woods BL; Tan B; Behren A; Cebon J; McKeown SJ
Oncotarget; 2016 Jul; 7(27):41186-41202. PubMed ID: 27172792
[TBL] [Abstract][Full Text] [Related]
16. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Bmi-1 suppresses epithelial‑mesenchymal transition in melanoma.
Liu Y; Chu Z; Li Q; Peng B; Xu S; Lian CG; Geng S
Oncol Rep; 2017 Jan; 37(1):139-146. PubMed ID: 27878257
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells.
Jia J; Zheng Y; Wang W; Shao Y; Li Z; Wang Q; Wang Y; Yan H
Mol Med Rep; 2017 Jan; 15(1):240-248. PubMed ID: 27922666
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1).
Noguchi K; Dincman TA; Dalton AC; Howley BV; McCall BJ; Mohanty BK; Howe PH
J Biol Chem; 2018 Jul; 293(29):11401-11414. PubMed ID: 29871931
[TBL] [Abstract][Full Text] [Related]
20. The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype.
Vandamme N; Denecker G; Bruneel K; Blancke G; Akay Ö; Taminau J; De Coninck J; De Smedt E; Skrypek N; Van Loocke W; Wouters J; Nittner D; Köhler C; Darling DS; Cheng PF; Raaijmakers MIG; Levesque MP; Mallya UG; Rafferty M; Balint B; Gallagher WM; Brochez L; Huylebroeck D; Haigh JJ; Andries V; Rambow F; Van Vlierberghe P; Goossens S; van den Oord JJ; Marine JC; Berx G
Cancer Res; 2020 Jul; 80(14):2983-2995. PubMed ID: 32503808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
